Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II brigatinib study in ALK fusion-positive metastatic solid tumors excluding NSCLC
jRCT2041210148Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoint: Confirmed objective response rate. Started May 2022; status: active, not recruiting.
02
Drugs
brigatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2041210148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210148.